You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Report: Mallinckrodt seeks sale of generic drug unit
Global Capital Markets & SPAC Activity – H1 2021
Gauging Supply Chain Risk In Volatile Times
Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals
The Future of Risk Management Digitization in Credit Risk Management
Mallinckrodt PLC is looking at the possibility of a sale of its generic drug unit, Reuters reported May 30, citing "people familiar with the matter."
A deal for the unit might be valued at about $2 billion. There is no guarantee the talks will lead to a deal, according to the sources.
The company has reportedly appointed Credit Suisse Group AG to run a sale process for the business.